Clinical Trials Logo

IGA Nephropathy clinical trials

View clinical trials related to IGA Nephropathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05824390 Active, not recruiting - IgA Nephropathy Clinical Trials

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

Start date: June 20, 2020
Phase: Phase 4
Study type: Interventional

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

NCT ID: NCT04578834 Active, not recruiting - IgA Nephropathy Clinical Trials

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

APPLAUSE-IgAN
Start date: January 25, 2021
Phase: Phase 3
Study type: Interventional

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

NCT ID: NCT04573920 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Atrasentan in Patients With Proteinuric Glomerular Diseases

AFFINITY
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

NCT ID: NCT04573478 Active, not recruiting - IgA Nephropathy Clinical Trials

Atrasentan in Patients With IgA Nephropathy

ALIGN
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

NCT ID: NCT03945318 Active, not recruiting - IgA Nephropathy Clinical Trials

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Start date: April 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).

NCT ID: NCT03453619 Active, not recruiting - Lupus Nephritis Clinical Trials

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Start date: January 22, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

NCT ID: NCT03218852 Active, not recruiting - IgA Nephropathy Clinical Trials

Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy

e-TOPplus
Start date: December 2016
Phase: Phase 4
Study type: Interventional

This study is an extended follow-up of the study (ClinicalTrials.gov ID: NCT01758120)-Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.

NCT ID: NCT03188887 Active, not recruiting - IgA Nephropathy Clinical Trials

Treatment of IgA Nephropathy According to Renal Lesions

TIGER
Start date: February 20, 2018
Phase: Phase 3
Study type: Interventional

TIGER study (Treatment of IgA nEphropathy according to Renal lesions) is a prospective openly randomized controlled study. The main objective is to evaluate the efficacy of early corticotherapy + Renin Angiotensin System (RAS) blockade or inhibitors of Sodium glucose transporter 2 (SGLT2i) (versus RAS blockade or SGLT2i alone) after two years of evolution in IgAN patients with severe histological lesions.

NCT ID: NCT01758120 Active, not recruiting - IgA Nephropathy Clinical Trials

Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy

TOPplus-IgAN
Start date: December 2012
Phase: Phase 4
Study type: Interventional

Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.